Clinical Trial Update: A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema [Phase 2]

View source ↗

Summary

A Phase 2 multi-center trial comparing a CCR2/5 receptor antagonist to Ranibizumab for diabetic macular edema was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• CCR2/5 receptor antagonist
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Pfizer | Conditions: Macular Edema, Diabetic | Phase 2 | Status: TERMINATED | Results posted: 2016-10-17